Boardroom Alpha
Boardroom Alpha
TSHA · Additional Proxy Materials (DEFA14A) · Filed April 22, 2026

Taysha Gene Therapies Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
April 22, 2026
Ticker
TSHA
Accession
0001193125-26-168533
Boardroom Alpha · Filing insights

Taysha Gene Therapies outlines its director slate for the 2026 meeting. Standard governance votes accompany the slate.

About Taysha Gene Therapies Inc
Market cap
$1.6B
1Y TSR
+135.3%
3Y TSR
+102.4%
Board grade
C-
Sector
Healthcare
CEO
Sean P Nolan
Last annual meeting: Jun 1, 2026 · View full Taysha Gene Therapies Inc profile →
DEFA14A
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No.)

 

 

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

 

Preliminary Proxy Statement

 

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 

Definitive Proxy Statement

 

Definitive Additional Materials

 

Soliciting Material under §240.14a-12

Taysha Gene Therapies, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

 

No fee required.

 

Fee paid previously with preliminary materials

 

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

 

 
 


LOGO

This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. To view the Notice and Proxy Statement and Annual Report, and to obtain directions to attend the meeting, go to: www.ProxyVote.com. Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the Internet. TAYSHA GENE THERAPIES, INC. 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS, TEXAS 75247 V90327-P46595 Your Vote Counts! TAYSHA GENE THERAPIES, INC. 2026 Annual Meeting Vote in advance by May 31, 2026 11:59 PM ET You invested in TAYSHA GENE THERAPIES, INC. and it’s time to vote! Stockholders of record as of the close of business on April 8, 2026 have the right to vote on proposals being presented at the 2026 Annual Meeting. THIS IS AN IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE STOCKHOLDER MEETING TO BE HELD ON JUNE 1, 2026. Get informed before you vote View the Annual Report and Notice and Proxy Statement online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 18, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Vote Virtually at the Meeting* Point your camera here and June 1, 2026 9:00 AM Eastern Time vote without entering a control number Virtually at: www.virtualshareholdermeeting.com/TSHA2026 *Please check the meeting materials for any special requirements for meeting attendance.


LOGO

Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Board Voting Items Recommends 1. To elect the Board’s Class III Director nominees, Sean P. Nolan and Laura Sepp-Lorenzino, Ph.D. to the Board of Directors to hold office until the 2029 Annual Meeting of Stockholders. Nominees: For 01) Sean P. Nolan 02) Laura Sepp-Lorenzino, Ph.D. 2. To ratify the selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the independent For registered public accounting firm of the Company for the year ending December 31, 2026. 3. To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers. For 4. To indicate, on a non-binding advisory basis, the preferred frequency of future stockholder advisory votes on the 1 Year compensation of the Company’s named executive officers. NOTE: In their discretion, the proxies are authorized to vote upon such other business as may properly come before the meeting or any adjournment, continuation, or postponement thereof. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V90328-P46595

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Taysha Gene Therapies Inc (TSHA)

Reference

Frequently asked questions

When did Taysha Gene Therapies Inc file this DEFA14A?
Taysha Gene Therapies Inc (TSHA) filed this Additional Proxy Materials (DEFA14A) with the SEC on April 22, 2026. The accession number assigned by EDGAR is 0001193125-26-168533.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Taysha Gene Therapies outlines its director slate for the 2026 meeting. Standard governance votes accompany the slate. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Taysha Gene Therapies Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Taysha Gene Therapies Inc has filed under CIK 1806310, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer